About Us
Cimeio Therapeutics
These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. Shielded Cell and Immunotherapy Pairs and SCIP are trademarks of Cimeio Therapeutics, Inc.
Leadership
Thomas Fuchs
Chief Executive Officer
Lukas Jeker, MD/PhD
Founder, SVP Gene Editing
Daniel Stark, PhD
Chief Manufacturing Officer
Stefanie Urlinger, PhD
Chief Scientific Officer
Thomas Fuchs
Chief Executive Officer
Lukas Jeker, MD/PhD
SVP Gene Editing
Daniel Stark, PhD
Chief Manufacturing Officer
Stefanie Urlinger, PhD
Chief Scientific Officer
Scientific Advisory Board
Suneet Agarwal, MD, PhD
Assoc. Prof. Harvard Medical School
Jeff Bluestone, PhD
CEO, Sonoma Bio
Toni Cathomen, MD
Prof. University of Freiburg
Corey Cutler, MD, MPH, FRCPC
Assoc. Prof. Harvard Medical School
Fyodor Urnov, PhD, Chair
Prof. University of California Berkeley
Suneet Agarwal, MD, PhD
Jeff Bluestone, PhD
Toni Cathomen, MD
Corey Cutler, MD, MPH, FRCPC
Fyodor Urnov, PhD, Chair
Board of Directors
Markus Enzelberger, Ph.D.
Independent Director
Thomas Fuchs
Chief Executive Officer
Alexander Mayweg, Ph.D.
Chairman of the Board
Luca Santarelli
Independent Director
Michael Tomsicek
Independent Director
Markus Enzelberger, Ph.D.
Independent Director
Thomas Fuchs
Chief Executive Officer
Alexander Mayweg, Ph.D.
Chairman of the Board
Luca Santarelli
Independent Director
Michael Tomsicek
Independent Director
Team
Julie Brault
Anna Camus
Valentin Do Sacramento
Laura Garcia Prat
Eva-Maria Grossjohann
Tanja Herrmann
Andreja Knezevic
Sophie Lackner
Frank Lehmann
Mathilde Testut
